Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04501796 · ClinicalTrials.gov registry record · Phase 1
A Trial of NT-I7 in COVID-19 (SPESELPIS)
A Phase 1 study, sponsored by NeoImmuneTech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04501796: Clinical Trial Phase 1 study, sponsored by NeoImmuneTech.
NCT04501796 is a Phase 1 study that was terminated before completion, run by NeoImmuneTech. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04501796, a Phase 1 study, was terminated before completion, sponsored by NeoImmuneTech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): * Safety of a single dose of NT-I7 * The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
Primary Outcome
Assessment of the number and severity of AEs possibly, probably, or definitely related to study drug evaluated at 7 and 30 days.
Interventions
- DRUG Double-Blind Placebo
- DRUG Double-Blind NT-I7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-11-27 |
| Est. Completion | 2023-02-23 |
| Phase | Phase 1 |
Why NCT04501796 stopped before completion
NCT04501796 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Double-Blind Placebo is the first listed.
NCT04501796 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04501796 about?
NCT04501796 is a clinical study titled "A Trial of NT-I7 in COVID-19 (SPESELPIS)". The main purposes of this study is to determine the following in participants with mild coronavirus disease 2019 (COVID-19): * Safety of a single dose of NT-I7 * The immunological effects of NT-I7 on peripheral lymphocyte counts in COVID-19 patients.
What is the current status of trial NCT04501796?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2020-11-27. Estimated completion is 2023-02-23.
What interventions are being tested in trial NCT04501796?
The interventions under investigation include: Double-Blind Placebo (DRUG), Double-Blind NT-I7 (DRUG).
Who is sponsoring clinical trial NCT04501796?
This trial is sponsored by NeoImmuneTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04501796's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI